Research Reports

Key takeaways

Revenue increased 8.9% to $193.5M, driven by higher gross price and favorable gross-to-net adjustments for Xtampza ER and Belbuca.

Operating income rose 42.5% to $30.9M as revenue growth outpaced operating expense increases.

Net income surged to $14.5M from $2.4M, benefiting from operating leverage and lower interest expense.

Management expects to close the Azstarys acquisition in Q2 2026, funded by cash and a delayed draw term loan.

Full analysis

Revenue Growth Driven by Portfolio Strength

Operating Leverage and Profitability

Cash Flow and Balance Sheet Strength

Outlook and Strategic Priorities

Management expects to close the acquisition of Azstarys in the second quarter of 2026, funded by cash on hand and a delayed draw term loan. The company continues to focus on its portfolio of pain management products and remains confident in its ability to generate strong cash flows. However, if demand for Xtampza ER and future related products does not meet expectations, the company may not realize the anticipated return on investment, which could negatively impact financial condition and results of operations.